Efficiency analysis in early application of PCSK-9 inhibitor for treatment of acute ST segment elevation myocardial infarction patients with spontaneous recanalization of culprit vessels

WANG Tong; WANG Fengyun; SU Dongsheng; ZHU Yinchuan; ZHANG Qianqian; HUANG Xin; TANG Jianmin

doi:10.7619/jcmp.20211019

Journal of Clinical Medicine in Practice > 2021 > 25(11): 77-81. > DOI: 10.7619/jcmp.20211019

WANG Tong, WANG Fengyun, SU Dongsheng, ZHU Yinchuan, ZHANG Qianqian, HUANG Xin, TANG Jianmin. Efficiency analysis in early application of PCSK-9 inhibitor for treatment of acute ST segment elevation myocardial infarction patients with spontaneous recanalization of culprit vessels[J]. Journal of Clinical Medicine in Practice, 2021, 25(11): 77-81. DOI: 10.7619/jcmp.20211019

Citation:

PDF (642 KB)

Efficiency analysis in early application of PCSK-9 inhibitor for treatment of acute ST segment elevation myocardial infarction patients with spontaneous recanalization of culprit vessels

Cardiovascular Department of Internal Medicine, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014

More Information

Received Date: March 09, 2021
Available Online: June 14, 2021
Published Date: June 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To observe the clinical efficacy of early application of PCSK-9 inhibitors in treatment of acute ST segment elevation myocardial infarction (STEMI) patients with spontaneous recanalization of culprit vessels.
Methods A total of 124 STEMI patients with spontaneous recanalization of culprit vessels after percutaneous coronary intervention (PCI) from January to June 2020 in the Second Affiliated Hospital of Zhengzhou University were selected, they were divided into evolocumab group (n=70) and control group (n=54) according to the use of PCSK-9 inhibitor. The success rate of operation and blood flow classification of thrombolysis in myocardial infarction (TIMI) were compared between the two groups, and echocardiography and cardiac function markers were used to evaluate the recovery of cardiac function. Incidence rates of major adverse cardiovascular events (MACE) and clinical adverse events in 6 months of follow up were recorded.
Results The average hospital stay, low density lipoprotein cholesterol, N-terminal pro-brain natriuretic peptide, preoperative and postoperative high-sensitivity C reactive protein levels of the patients in the evolocumab group were significantly lower than those in the control group, while the left ventricular ejection fraction, preoperative and postoperative ratios of grade 3 blood flow of TIMI were significantly higher than those in the control group (P < 0.05). The incidence of MACE within 6 months of follow-up in the evolocumab group was significantly lower than that in the control group (P < 0.05).
Conclusion For STEMI patients with spontaneous recanalization of culprit vessels, early application of PCSK-9 inhibitor can increase myocardial reperfusion volume and improve cardiac function and prognosis.

FullText(HTML)

References (21)

References

[1]	李建辉, 魏璇, 鲍雪, 等. 急性ST段抬高型心肌梗死介入术后心肌内出血的相关因素分析[J]. 中国动脉硬化杂志, 2021, 29(2): 135-142. doi: 10.3969/j.issn.1007-3949.2021.02.008
[2]	PAPADEMETRIOU V, STAVROPOULOS K, PAPADOPOULOS C, et al. Role of PCSK9 inhibitors in high risk patients with dyslipidemia: focus on familial hypercholesterolemia[J]. Curr Pharm Des, 2018, 24(31): 3647-3653. http://www.ncbi.nlm.nih.gov/pubmed/30317985
[3]	SABATINE M S, DE FERRARI G M, GIUGLIANO R P, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER[J]. Circulation, 2018, 138(8): 756-766. doi: 10.1161/CIRCULATIONAHA.118.034309
[4]	HÄNER J D, SIONTIS G C, STOLLER M, et al. Spontaneous recanalization of a chronically occluded right coronary artery-When nature is more successful than technology[J]. Int J Cardiol, 2016, 214: 161-162. doi: 10.1016/j.ijcard.2016.03.174
[5]	LI X M, LI B Y, GAO J, et al. Influence of angiographic spontaneous coronary reperfusion on long-term prognosis in patients with ST-segment elevation myocardial infarction[J]. Oncotarget, 2017, 8(45): 79767-79774. doi: 10.18632/oncotarget.19338
[6]	中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2010, 38(8): 675-690. doi: 10.3760/cma.j.issn.0253-3758.2010.08.002
[7]	赵一品, 季莹莹, 王丰云, 等. 纤维蛋白原与白蛋白比值预测急性ST段抬高型心肌梗死患者梗死相关动脉自发再通的价值[J]. 中华心血管病杂志, 2019, 47(2): 123-128. doi: 10.3760/cma.j.issn.0253-3758.2019.02.009
[8]	WANG Y, YAN B P, NICHOL M B, et al. Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: a retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients[J]. Int J Cardiol, 2017, 249: 18-24. doi: 10.1016/j.ijcard.2017.07.016
[9]	STONE N J, ROBINSON J G, LICHTENSTEIN A H, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2014, 129(25 Suppl 2): S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a
[10]	李建军. 2019年ESC/EAS血脂管理指南要点解读[J]. 中国循环杂志, 2019, 34(S1): 58-59. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH2019S1013.htm
[11]	DEEDWANIA P, MURPHY S A, SCHEEN A, et al. Efficacy and safety of PCSK₉ inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial[J]. JAMA Cardiol, 2021, 6(2): 139-147. doi: 10.1001/jamacardio.2020.3151
[12]	KOSKINAS K C, WINDECKER S, PEDRAZZINI G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)[J]. J Am Coll Cardiol, 2019, 74(20): 2452-2462. doi: 10.1016/j.jacc.2019.08.010
[13]	KOREN M J, LUNDQVIST P, BOLOGNESE M, et al. Anti-PCSK₉ monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase Ⅲ clinical trial of evolocumab[J]. J Am Coll Cardiol, 2014, 63(23): 2531-2540. doi: 10.1016/j.jacc.2014.03.018
[14]	ROBINSON J G, NEDERGAARD B S, ROGERS W J, et al. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial[J]. JAMA, 2014, 311(18): 1870-1882. doi: 10.1001/jama.2014.4030
[15]	ALMONTASHIRI N A, VILMUNDARSON R O, GHASEMZADEH N, et al. Plasma PCSK₉ levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies[J]. PLoS One, 2014, 9(9): e106294. doi: 10.1371/journal.pone.0106294
[16]	LANDLINGER C, POUWER M G, JUNO C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE^*3Leiden. CETP mice[J]. Eur Heart J, 2017, 38(32): 2499-2507. doi: 10.1093/eurheartj/ehx260
[17]	LIU A, FROSTEGÅRD J. PCSK₉ plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque[J]. J Intern Med, 2018: 12758. doi: 10.1111/joim.12758
[18]	CHENG J M, OEMRAWSINGH R M, GARCIA-GARCIA H M, et al. PCSK₉ in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study[J]. Atherosclerosis, 2016, 248: 117-122. doi: 10.1016/j.atherosclerosis.2016.03.010
[19]	郭远林, 陈纪林. 2019年欧洲血脂异常管理指南对我国临床实践的启示[J]. 中国循环杂志, 2020, 35(2): 105-107. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH202002001.htm
[20]	NAVARESE E P, KOLODZIEJCZAK M, WINTER M P, et al. Association of PCSK₉ with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK₉-REACT study[J]. Int J Cardiol, 2017, 227: 644-649. doi: 10.1016/j.ijcard.2016.10.084
[21]	YUAN F, GUO L, PARK K H, et al. Ossabaw pigs with a PCSK₉ gain-of-function mutation develop accelerated coronary atherosclerotic lesions: a novel model for preclinical studies[J]. J Am Heart Assoc, 2018, 7(6): e006207. http://europepmc.org/abstract/MED/29572319

Cited By

Cited by

Periodical cited type(7)

1.	唐茁栋，王明友，王洪平，李亭燕，王川，刘绍江. 胫骨平台骨折术前下肢深静脉血栓形成列线图预测模型构建与验证. 创伤外科杂志. 2025(01): 43-49 .
2.	郭荣，余墨声，赵月强，朱占永，罗莎，谭植襄，陶瑞，王芳. 齐踝及齐膝弹力裤对大腿吸脂病人深静脉血栓预防效果的对比研究. 临床外科杂志. 2024(05): 541-544 .
3.	宋峰，方灿军，胡靖，陈义. 中青年髋部骨折患者术前深静脉血栓形成的危险因素及列线图预测模型的构建. 实用临床医药杂志. 2023(12): 32-37 . 本站查看
4.	李慧婷，汤益，刘燕. 彩色多普勒超声在下肢深静脉血栓诊断及溶栓效果评估中应用价值分析. 临床医学工程. 2023(07): 889-890 .
5.	杜茜，蔡晨盛. 彩色多普勒超声结合D-二聚体在偏瘫患者孤立性小腿肌间静脉血栓诊断中的价值. 现代医用影像学. 2023(11): 2113-2116 .
6.	戴清月，高燕玲，卢金华，孙情，苏清岩，程熙. 老年脊髓损伤患者临床特征的回顾性分析. 中国医药科学. 2022(23): 183-187+196 .
7.	王杨，王晓春，李俊杰，高翔. 高频超声联合D-二聚体、纤维蛋白原对小腿肌间静脉丛血栓形成的诊断价值. 血管与腔内血管外科杂志. 2022(12): 1494-1498 .

Other cited types(0)

Get Citation

PDF

XML

Article views (371) PDF downloads (15) Cited by(7)

Turn off MathJax

Article Contents

Abstract

References

Efficiency analysis in early application of PCSK-9 inhibitor for treatment of acute ST segment elevation myocardial infarction patients with spontaneous recanalization of culprit vessels

Abstract

References

Cited by

Periodical cited type(7)

Other cited types(0)

Catalog

Export File

Citation

Format

Content